Drugs / SCT1000
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04921111 | Jul 2021 → Jul 2022 | — | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06041061 | Aug 2023 → Mar 2024 overdue | carcinoma, human papilloma virus infection | Sinocelltech Ltd. | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05060484 Comparator | Oct 2021 → May 2022 | — | Sinocelltech Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCT1000 | “SCT1000 is a recombinant 14-valent human papillomavirus vaccine (insect cell) that covers all 12 WHO-recognized high-risk oncogenic HPV subtypes” NCT06041061 ↗ |
| Modality | Vaccine | “Recombinant 14 valent human papillomavirus vaccine (6,11,16,18,31,33,35,39,45,51,52,56,58,59) (insect cells)” NCT04921111 ↗ |
| Route | Intramuscular | “intramuscular injection of the upper arm deltoid muscle” NCT06041061 ↗ |